< Back Pharmefex and Dahlia-Consulting announce the creation of a strategic partnership Mar 23, 2023 Pharmefex ( www.pharmefex.com ) and Dahlia Consulting ( dahlia-consulting.com ) are pleased to announce the formation of a strategic partnership. This partnership is based on shared values and standards of quality and expands the scope of outstanding service Dahlia and Pharmefex provide their clients. Dahlia is a well-respected global consulting firm in the life science industry providing a multitude of services to start ups as well as mature companies in project and program management, facility construction management, business operations, operational readiness, Quality and Compliance, to market access & reimbursement. Pharmefex is a leading provider of CMC technical consulting, and provides services ranging from strategic support to process & method development, CDMO selection and oversight, technology transfers, CMC submissions, inspections and GMP manufacturing support for recombinant proteins, and cell and gene therapy products. Through this partnership Pharmefex and Dahlia are poised to improve on our already high standards of service to our clients worldwide. Previous Next

< Back Why Outsourced Project Management and Regulatory Compliance Are the Future of Biotech Jun 4, 2025 In today’s fast-paced life sciences landscape, biotechnology companies are under pressure to move faster, reduce costs, and remain compliant — all while navigating increasingly complex global regulatory frameworks. As a result, outsourcing project management and regulatory compliance has emerged as a strategic imperative, not just a cost-saving tactic. Biotech companies — from early-stage startups to large-scale manufacturers — are increasingly turning to biotech consulting services to manage regulatory operations, ensure quality, and accelerate development timelines through specialized outsourced support. Project Management: The Engine Behind Biotech Outsourcing Biotech project management is more than tracking deliverables — it’s the strategic framework that connects internal priorities with outsourced execution. Experienced project managers ensure alignment across cross-functional teams and external vendors, keeping regulatory milestones such as INDs, CTAs, BLAs, and MAAs on track. By overseeing timelines, vendor communications, CMC documentation, and compliance workflows, project managers minimize risks and keep programs moving forward efficiently. When paired with regulatory outsourcing, professional project leadership enhances execution speed, reduces costly delays, and ensures regulatory readiness — giving biotech companies a true competitive advantage. The Shift Toward Outsourcing in Biotech As development costs rise, timelines tighten, and global regulatory demands intensify, in-house teams often struggle to maintain momentum. Economic shifts, workforce reductions, and organizational restructuring have further limited internal capacity — making outsourcing not only practical, but necessary. Strategic regulatory outsourcing enables biotech companies to tap into specialized expertise, recover lost labor capacity, and optimize operational efficiency without compromising quality or compliance. Key Benefits of Regulatory and Project Management Outsourcing Cost Efficiency : Reduce overhead by engaging biotech regulatory experts instead of scaling internal teams. Speed and Scalability : Flexibly expand or reduce services based on development stage — from IND preparation to commercial readiness. Access to Expertise : Work with consultants experienced in FDA, EMA, MHRA, and global regulatory requirements. Focus on Innovation : Free up internal resources to prioritize scientific advancement and product innovation. Improved Compliance : Maintain quality systems and inspection readiness with expert-led documentation and oversight. This approach is particularly valuable for advanced therapy developers in cell and gene therapy, ADCs, and complex biologics. A Long-Term Strategy for Modern Biotech Companies The future of biotech is lean, agile, and strategically outsourced. Rather than building large internal regulatory or quality teams, companies are forming long-term partnerships with trusted biotech consulting firms that offer plug-and-play support across the product lifecycle. Biotech companies are now outsourcing critical functions such as: Regulatory affairs strategy and agency interaction CMC documentation and technical writing Quality system development, gap assessments, and audits Global compliance planning End-to-end project and program management This model reduces internal burden, improves execution, and accelerates time to market — especially for innovative therapeutic programs under tight timelines and high regulatory scrutiny. Why Partner with Pharmefex? Pharmefex is a leading biotech consulting firm with deep expertise in regulatory strategy, CMC development, and project execution. Our team supports companies at every stage of development — from preclinical through commercialization — with flexible, expert-driven services tailored to your program’s needs. We specialize in: Regulatory submissions (IND, CTA, BLA, MAA) Biotech project management and strategic planning CMC development and documentation Quality system implementation and audits Vendor oversight and tech transfer support Whether you need to fill internal gaps, scale efficiently, or optimize your regulatory execution, Pharmefex is here to help. 📩 Contact Pharmefex today to learn how our expert regulatory outsourcing and biotech project management services can help you reduce risk, improve execution, and accelerate success. Previous Next

< Back Pharmefex and Jeff Yuen and Associates announce creation of Partnership Jul 11, 2018 Pharmefex ( www.pharmefex.com ) and Jeff Yuen and Associates ( www.jeffyuen.com ) are pleased to announce the formation of a strategic partnership. Jeff Yuen & Associates, Inc. (JYA) is a wellrespected domestic and international consulting firm comprised of former regulators and industry experts. JYA provide GMP audit and training, regulatory services, facility reviews, mock inspections and other services to clients worldwide. Pharmefex provides technical, CMC, and strategic support to streamline process development, accelerate time to market, reduce cost of goods, manage technology transfers, prepare CMC submissions, and prevent and resolve manufacturing and compliance problems for recombinant proteins, and cellular immunotherapy products. This partnership is based on shared values and standards of quality and expands the scope of outstanding service JYA and Pharmefex can provide their clients. Previous Next

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Outsourcing and Supply Chain Management About Pharmefex offers comprehensive CMC outsourcing and supply chain management services to help you develop outsourcing strategies that meet your needs and requirements throughout all stages of your product’s lifecycle. During product development, we can manage all activities including cell line development, cell bank preparation and testing, process development, analytical method development, and formulation development. We can support all nodes of the supply chain from the procurement of raw materials to managing outsourced drug substance and drug product manufacturing and overseeing the packaging, labeling, and distribution of finished goods. We can assist you in identifying and selecting contract service providers by developing detailed requests for information or proposal, performing technical site visits and compliance audits, and reviewing proposals and other contractor-supplied material to support the selection of the most suitable contractor for your project. We can support the negotiation of service contracts, technology transfer for project initiation at a new contractor and ongoing management of outsourced activities. What We Can Do For You Our comprehensive approach can help you effectively plan and manage all stages of product development and commercialization by: Identifying, selecting, qualifying, and managing service providers for all your development, manufacturing, and quality needs Negotiating development, supply, and quality agreements Developing and implementing strategies for logistics and cold chain management throughout your supply chain Preparing or assessing systems for inventory planning and management Modeling and planning supply chains to help ensure consistent and on-time delivery of clinical trial material, integrate material planning with sales and operations planning, and maintenance of proper inventory levels Developing effective manufacturing facility strategies incorporating future utilization rates and plans for maximizing value of underutilized assets Assessing product supply chain risk and assisting with implementation of risk mitigation strategies, such as establishing secondary sources of suppliers Previous Next

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Product, Process & Analytical Development About Our extensive product, process and analytical development experience enables us to help you transition your products from discovery to the clinic and to market faster and with less expense and risk. Whether your product is in pre-clinical development, clinical trials, or already on the market, we can help increase its value by identifying opportunities for yield improvement, enhanced product quality, ease of scalability, greater process robustness, cost reductions, and reduced processing times. Our extensive experience working with CROs and CMOs can help you identify the best partners for your development and manufacturing needs and provide knowledgeable oversight of the development activities at your chosen vendor.We also have extensive experience in the development and implementation of suitable analytical methods to assess purity, safety, potency, and stability of your product at all stages of development and commercialization. In all cases, we help ensure that your manufacturing processes and analytical methods meet all relevant regulatory expectations and requirements. What We Can Do For You Whether you need our assistance to guide your staff in design, development and execution, or you need us to oversee and direct activities at CMOs and CROs, we can help you in: Cell line development from selection of optimal expression systems to preparation and characterization of cell banks Upstream and downstream process development, including design of experiments, data review, and process evaluation and optimization Analytical method development, qualification, and validation to support process development, product characterization, in-process and final product testing and stability Drug product process development from formulation design and development to advice on container/closure systems Preparation of pre- and post-approval comparability plans to ensure smooth implementation of process changes throughout development Support for process development, technology transfer, and scale-up during outsourcing Preparation of validation master plans, process validation protocols, and viral safety studies and oversight of these activities Evaluation of the feasibility, cost, benefit, and regulatory impact of new process technologies Previous Next

< Back Pharmefex Brief on FDA PreCheck and AMT Sep 30, 2025 Introduction The FDA has recently introduced two initiatives: PreCheck and the Advanced Manufacturing Technologies (AMT) Designation Program. Together, they aim to strengthen U.S. pharmaceutical manufacturing. Both are designed to reduce reliance on foreign suppliers, foster the adoption of innovative approaches, and create more resilient supply chains. The FDA PreCheck Program PreCheck establishes a risk-based regulatory pathway to expedite the review of new U.S. pharmaceutical manufacturing facilities. It works in two phases: an early facility readiness phase, where companies can engage FDA during design and construction, followed by an application submission phase that integrates this feedback into the drug application process. The program promises clearer communication with FDA reviewers, faster and more predictable timelines, and ultimately, greater confidence in domestic capacity. By assessing facilities earlier in development, PreCheck reduces uncertainty for sponsors while advancing the FDA’s broader goal of supporting U.S.-based production. To introduce the framework and gather stakeholder input, FDA will host a public meeting on September 30, 2025, at its White Oak Campus, with virtual participation available. The meeting will highlight PreCheck’s draft structure and explore challenges to onshoring that remain within FDA’s authority to address. The AMT Designation Program Whereas PreCheck focuses on facilities, the AMT program encourages the use of innovative technologies such as continuous manufacturing, digital twins, or process analytical technologies (PAT), that can improve quality, efficiency, and flexibility in drug production. Sponsors, CDMOs, and technology developers can request FDA designation for specific technologies. Those accepted benefit from enhanced communication with agency experts, early regulatory advice, and a clearer path to adoption. In doing so, AMT fosters innovation while directly supporting efforts to expand capacity and safeguard supply chains. How They Work Together PreCheck and AMT are designed to be complementary. PreCheck addresses the readiness and predictability of domestic manufacturing facilities, while AMT provides a framework for advancing new technologies within those facilities. Together, they align with FDA’s broader policy objective of modernizing U.S. pharmaceutical manufacturing and reducing reliance on foreign sources. By combining early facility engagement with support for advanced technologies, these initiatives have the potential to improve supply chain security, accelerate patient access to critical medicines, and create a more efficient regulatory environment. Conclusion The launch of PreCheck and AMT marks a significant step in FDA’s strategy to promote innovation and resilience in U.S. drug manufacturing. For sponsors, contract manufacturers, and technology developers, engaging with these programs offers not only regulatory advantages but also a chance to demonstrate long-term commitment to robust, high-quality supply chains. At Pharmefex, we help clients navigate these evolving pathways , whether it’s integrating PreCheck into facility readiness plans, aligning CMC strategies with AMT expectations, or preparing inspection-ready dossiers. Our expertise ensures that sponsors can move confidently through these new frameworks, turning regulatory opportunities into competitive advantages. For more information or to register for the September 30, 2025 public meeting, visit the FDA website or contact PublicEngagement@fda.hhs.gov . Previous Next

< Back Pharmefex and Beck Life Sciences announce creation of strategic collaboration Sep 20, 2019 Pharmefex LLC and Beck Life Sciences LLC, a leading Engineering, Procurement, and Construction firm, are pleased to announce the formation of a strategic collaboration. “This is an exciting time to be in the life sciences industry. Through our partnership with Pharmefex, we can broaden our experience, strengthen our relationships within the industry, and continue to innovate for our clients,” said Steve Springer, Director of Life Sciences at Beck. “The relationship with Beck enables us to offer a more extensive portfolio of services to our clients while remaining 100% focused on our mission of being the premier provider of CMC consulting expertise for biologics and cell therapy products,” said Ali Siahpush, President of Pharmefex. Pharmefex provides technical, CMC, and strategic support to streamline development and commercialization of biologics and cell therapy products worldwide. As part of this agreement, Beck Life Sciences will be able to extend its broad expertise and unmatched technologies to Pharmefex clients worldwide. Pharmefex will, in turn, make available it’s extensive experience and network of biologics and cell therapy expertise to Beck Life Sciences’ clients worldwide. Previous Next

< Back The Rise of ADCs. Why Outsourcing and Supply Chain Diversification Are Critical to Success May 21, 2025 Antibody-drug conjugates (ADCs) are transforming oncology drug development. These next-generation therapies combine the targeting power of monoclonal antibodies with potent cytotoxic drugs, delivering treatment directly to cancer cells while minimizing harm to healthy tissue. With strong clinical data, multiple recent FDA approvals, and increasing investor interest, ADCs are one of the fastest-growing areas in biotech. Major pharmaceutical companies—including Daiichi Sankyo, Seagen, and ImmunoGen—have made significant strides in ADC development, leading to landmark licensing deals and acquisitions. ADCs: High Potential, High Complexity Despite their clinical promise, ADCs are among the most challenging biologics to manufacture. The process involves multiple highly technical steps, including antibody production, cytotoxic payload synthesis, chemical conjugation, purification, and sterile fill-finish. Each stage requires tight control, specialized equipment, and often high-containment facilities due to the toxicity of the payload. Most biotech companies lack the internal infrastructure to handle this complexity, especially at scale. As a result, the majority of ADC developers now outsource manufacturing to contract development and manufacturing organizations (CDMOs). This trend is not only practical—it’s essential. CDMOs offer established infrastructure, deep technical expertise, and regulatory-ready platforms that help accelerate timelines while maintaining compliance. According to Pharmaceutical Technology , around 70–80% of ADC developers rely on CDMOs for at least part of their production. These partnerships allow developers to focus on their clinical and commercialization strategies while entrusting complex operations to experienced specialists. Why Supply Chain Diversification Is a Strategic Imperative In today’s volatile global environment, supply chain resilience has become just as important as scientific innovation. ADCs depend on a limited set of critical materials—particularly linker-payloads, which are often manufactured in specific regions like China or India. This concentration of supply poses serious risks. Recent geopolitical tensions and regulatory shifts, such as the proposed U.S. Biosecure Act , have prompted companies to rethink their global sourcing strategies. The risk of production halts due to export controls, political instability, or shipping delays is simply too high for programs operating on tight clinical or commercial timelines ( Wall Street Journal ). To manage these risks, developers are now prioritizing supply chain diversification—engaging multiple suppliers across geographies, qualifying backup CDMOs, and strengthening logistics strategies to ensure continuity. A proactive approach to supply chain planning is no longer optional; it’s a strategic requirement for ADC success. How Pharmefex Supports ADC Development and Manufacturing Resilience At Pharmefex, we help biotech and pharmaceutical companies navigate the unique challenges of ADC development. Our team has extensive expertise in regulatory affairs, CMC strategy, and complex manufacturing workflows. We support clients across the full development lifecycle—from early planning to commercial readiness—with a focus on reducing risk and maintaining momentum. We work closely with clients to identify and manage CDMO partnerships, ensuring alignment on technical capabilities, quality systems, and scalability. Our supply chain experts assess geographic and operational risk, develop diversification plans, and support raw material sourcing strategies to ensure continuity across every step of production. Whether you’re procuring high-potency cytotoxins, planning global logistics, or preparing for tech transfer, we help you stay ahead of risk and on track for success. Looking to advance your ADC program with confidence? Pharmefex provides end-to-end support for outsourcing strategy, supply chain management, and regulatory compliance. Contact us to learn how we can help build a more resilient and efficient path to market. Previous Next

< Back Why Biotech Developers Must Act Now on Nitrosamine Risk Management Jun 10, 2025 As scientific understanding of nitrosamine impurities deepens, regulatory agencies are preparing to significantly raise the bar on acceptable risk levels — and the pharmaceutical industry must be ready to respond. On May 11, 2025 , the International Council for Harmonisation (ICH) released a Final Concept Paper outlining its intent to revise the ICH M7(R2) guideline. The revision, led by the ICH M7 Nitrosamine Subgroup, focuses on risk assessment and control of mutagenic nitrosamines in drug substances and drug products. With regulatory adoption expected across the U.S., EU, and other key regions, this development signals a new chapter in impurity control. What Are Nitrosamines, and Why the Heightened Concern? Nitrosamines are a class of chemical compounds that can form during drug manufacturing or storage — often through interactions between amines, nitrites, solvents, or packaging materials. While some nitrosamines are considered relatively harmless, others such as NDMA , NDEA , and related analogs are recognized as probable human carcinogens . Since their unexpected detection in widely used drugs like sartans , ranitidine , and metformin , nitrosamines have triggered product recalls, regulatory warnings, and deeper investigations into how they form and how they can be controlled. Their ability to appear unpredictably and at trace levels — yet still pose serious long-term health risks — has made them a top priority for regulators worldwide. What’s Changing with the New Guidance? The forthcoming ICH M7(R3) revision will introduce more precise and proactive strategies for nitrosamine detection and control, including: Stricter acceptable intake (AI) thresholds , with many nitrosamines expected to fall below 18 ng/day Adoption of structure–activity relationship (SAR)-based screening approaches to proactively identify mutagenic potential Enhanced emphasis on risk-based assessments that account for total daily intake across combination products Expanded scope of control , including raw materials, excipients, reagents, and manufacturing equipment Greater focus on root cause investigation , supplier qualification , and preventive controls , especially for contract development and manufacturing organizations (CDMOs) These updates reflect a shift toward lifecycle-based impurity management , requiring sponsors to address nitrosamine risk early and systematically across the entire development process. Why Early Planning Is Critical for Biotech Developers For emerging biopharma companies and lean development teams, these evolving guidelines represent more than a regulatory hurdle — they are a potential roadblock to approvals if not addressed early and thoroughly. Failure to meet nitrosamine expectations could lead to: IND or BLA rejections Clinical trial delays or holds Additional stability or reformulation studies Market withdrawals, recalls, or reputational damage What’s often overlooked — and now essential — is the quality and control of raw materials, intermediates, and final drug substances . Nitrosamine formation can originate upstream from reagents, solvents, or contaminated excipients and go undetected until late-stage testing or post-market review. That’s why supplier qualification, traceability, and comprehensive impurity testing across the entire supply chain must be embedded early in development. With the FDA and ICH aligning to raise the bar, companies must now integrate nitrosamine control into their core CMC strategy — not as a late-stage fix, but as a proactive, cross-functional safeguard for regulatory success and patient safety. How Pharmefex Helps Clients Navigate Compliance, CDMO Selection & Supply Chain Strategy At Pharmefex, we understand that nitrosamine mitigation is not just a testing challenge — it’s a strategic, regulatory, and operational imperative . Our team offers deep expertise across regulatory CMC , quality assurance , and CDMO sourcing and oversight , helping clients embed impurity risk control into every phase of development. We support clients by: Identifying and qualifying CDMOs with advanced nitrosamine detection, validated methods, and compliance readiness Developing risk-based impurity control strategies aligned with ICH and FDA expectations Designing raw material and intermediate testing strategies that detect and eliminate root causes early Assisting with supplier qualification, vendor audits , and supply chain mapping to ensure quality and traceability Supporting robust documentation and readiness for IND, BLA, and global submissions Pharmefex’s agile model allows biotech teams to stay ahead of evolving guidelines without increasing internal overhead , enabling scalable compliance, reduced development risk, and greater regulatory confidence. Final Thoughts The May 2025 ICH concept paper signals a critical shift: drug developers must treat nitrosamine control as a foundational component of quality and regulatory strategy . As impurity limits tighten and regulatory expectations rise, the companies that prepare now will be best positioned to avoid costly delays — and bring safer therapies to patients faster. Pharmefex is ready to help you build a future-ready strategy. Reach out today to learn how our regulatory, quality, and CDMO expertise can support your development goals in this evolving landscape. Previous Next

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Risk Management About Ever since introduction of the QBD approach into the CMC review process in 2004, the concept of risk based analysis, development, and management have gained significantly more traction in pharma and biopharma. In 2006, ICH Q9 outlined how Quality Risk Management can be applied to various elements across the product life cycle. This document also outlined many tools and analyses which could be used fo this purpose. While the concept was introduced as a means of improving and simplifying the process, without the right experience, the application of either QBD or risk management can seem overwhelming and complex. Contact us today to find out how we can help you. What We Can Do For You Our hands on experience in risk management and the application of risk analysis tools and techniques can take the complexity out of the picture and help you to take advantage of this powerful approach for: Identification of your product critical quality attributes (CQAs) Establishement of product specifications Prioritization of your development studies and control the scope of your validation Assist you in ongoing investigations (manufacturing, product complaints, etc.) Materials management (supplier assessments, product storage) Laboratory control and stability studies (retest periods and out of specfication investigations) Facility, equipment and utilities (design, qualification, calibration, etc.) Process characterization and process control Previous Next

< Back Pharmefex and CDDG announce creation of strategic Partnership Feb 1, 2018 Pharmefex ( Pharmefex.com ) and the Cascadia Drug Development Group (CDDG; theCDDG.com ) are pleased to announce the formation of a strategic partnership. Pharmefex specializes in Chemistry, Manufacturing and Controls (CMC) and helps organizations to streamline process development, accelerate time to market, reduce cost of goods, manage technology transfers, prepare regulatory submissions, and prevent and resolve manufacturing and compliance problems for recombinant proteins, and cellular immunotherapy products. CDDG provides oversight of drug development from discovery to early clinical development and offers subject matter expertise in several key translational sciences through their network of vetted affiliates. This partnership is based on shared values and standards of quality, and expands the scope of outstanding service CDDG and Pharmefex can provide their clients. Previous Next

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Manufacturing Strategy & Operations About Pharmefex is devoted to helping you make sound operational decisions to support all your manufacturing, outsourcing, and facility requirements. We can help you manage outsourcing projects, conceive and implement strategies to build optimal development and manufacturing organizations, effectively communicate your CMC strategy, and efficiently manage your workflow to accelerate product development. We can also help you determine the optimal use or market for your existing manufacturing facilities. If you are struggling with the difficult choice between capital investments in manufacturing facilities and infrastructure or outsourcing to support your short and long term manufacturing needs, we can provide guidance and recommendations that take into consideration the composition and timing of your product portfolio, the costs of building versus outsourcing, and the risks associated with development into the analysis. What We Can Do For You We can provide support for capital investments in new facility construction or for your outsourced manufacturing programs by: Providing input into equipment and materials selection and procurement Identifying outsource partners including CMOs and CROs that are the best fit for your requirements and manage CMO or CRO selection process Performing rigorous cGMP compliance audits of your facility or your selected CMO to insure appropriate sustainable regulatory compliance for your products Assisting in the design and construction of your manufacturing facility from preliminary technical and economic evaluations through start-up and validation Reviewing master and executed batch and testing records, and serve as person-in-plant during manufacturing campaigns at your CMO We are experts in facilities, equipment, process, and analytical method validation. We can prepare comprehensive Validation Master Plans and assist you in establishing documentation standards that are practical and compliant. Using our extensive library of protocols and procedures, we can prepare validation protocols, standard operating procedures, quality test methods, and production batch records. We can help you improve process performance following product commercialization, speed investigations of manufacturing deviations, or troubleshoot technical challenges. We can also optimize ongoing manufacturing operations for both clinical and commercial campaigns by developing staffing models, cost of goods models, operational efficiency programs, and cost reduction strategy recommendations. Previous Next